Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
Multiple sclerosis (MS) shares an immune-mediated origin with psoriasis. Long-term safety and efficacy data generated in Europe from usage of fumaric acid formulations in the latter disease constituted grounds to investigate their effects in MS patients. Dimethyl fumarate (DMF) was found to be the a...
Main Author: | Roberto Bomprezzi |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2015-01-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285614564152 |
Similar Items
-
Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
by: Silvia Boullosa-Lale, et al.
Published: (2021-03-01) -
Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
by: Ozel O, et al.
Published: (2019-12-01) -
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Nasim Nehzat, et al.
Published: (2021-01-01) -
Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective
by: Lorenzo Giovanni Mantovani, et al.
Published: (2019-07-01) -
[Budget impact analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]
by: Gianluca Furneri, et al.
Published: (2016-03-01)